跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Samchundang Pharm. Co., Ltd.

首页临床试验发起方与机构Samchundang Pharm. Co., Ltd.

Samchundang Pharm. Co., Ltd.

71 Jeyakgongdan 2-gil, Hyangnam-eup, Hwaseong, Gyeonggi, 韩国

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

9

7 进行中

药物批准

10

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

6

66.7%

3 期

2

22.2%

试验状态分布

进行中（未招募）

7

77.8%

已完成

1

11.1%

招募中

1

11.1%

相关临床试验

该机构主办的试验（9）

Bioavailability, Biopotency and Food effect study of SCD0503 compared to subcutaneous regular human insulin

May 202616 名受试者

This study is being done to compare the effectiveness and safety of study drug SCD411 (Aflibercept) and marketed product Eylea in treating wet Age-related Macular Degeneration disease which occurs in Eye.

进行中（未招募）

Jan 2021560 名受试者

A Phase III Study of SCD411 in Subjects with Neovascular Age-related Macular Degeneration

Nov 202068 名受试者

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

进行中（未招募）

Jul 2020576 名受试者

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

进行中（未招募）

Jun 2020560 名受试者

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

进行中（未招募）

Jun 2020573 名受试者

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

进行中（未招募）

May 2020560 名受试者

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

进行中（未招募）

May 2020560 名受试者

第 1 页，共 2 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

2

药物批准

PHILIPPINES

Philippines FDA

8

药物批准

近期批准

29 November 2023

31 October 2023

Fluorometholone Eye Drops

21 September 2021

Fluorometholone Eye Drops

资讯

暂无资讯文章

本页目录

概览
相关临床试验9
药物批准10
资讯

返回机构列表